Cerveau Technologies

Cerveau Technologies is a partner of Enigma Biomedical Group and Sinotau Pharmaceutical Group. Cerveau's vision is to globally develop diagnostics and technologies that positively impact patients with neurodegenerative diseases, including Alzheimer's disease. Cerveau Technologies has advanced MK-6240 into the mainstream of neurodegenerative disease research. Since then, MK-6240 has become a recognized leading imaging biomarker for Tau pathology, which is central to the progression of Alzheimer’s disease (AD). Cerveau licensed MK-6240 from Merck and is committed to establishing an extensive network of production facilities to support clinical research.